Perimeter Medical Imaging AI Moves to OTCQX Trading
Perimeter Medical Imaging AI, Inc. (OTC: PYNKF), a pioneering medical technology company, is set to begin trading on the OTCQX Best Market, a significant upgrade from its previous trading platform. This transition is scheduled to take effect at the start of business, marking a new chapter for the company as it aims to broaden its reach and strengthen its shareholder base in the United States.
Strategic Market Focus
According to Adrian Mendes, the Chief Executive Officer of Perimeter, many shareholders reside in the U.S., which is a primary target market for the company’s innovative S-Series optical coherence tomography (OCT) system as well as the anticipated AI-integrated B-Series product. This move to the OTCQX is not only a natural progression for the company but also aims to enhance visibility among potential investors.
Positive Momentum from Clinical Trials
In the previous quarter, Perimeter garnered attention when it reported promising topline results from a pivotal clinical study. This trial was conducted to support the anticipated submission for FDA premarket approval alongside its next-generation B-Series product featuring ImgAssist AI 2.0. The outcomes indicated a statistically significant reduction in patients with residual cancer during surgical procedures, showcasing the technology's potential to assist surgeons in achieving clearer margins and reducing the need for reoperations.
Understanding Perimeter's Technology
Perimeter's technology employs ultra-high-resolution imaging tools designed to significantly improve cancer surgery outcomes. The current S-Series OCT system offers real-time, cross-sectional visualizations of excised tissues at the cellular level, allowing for improved decision-making during surgeries. Meanwhile, the upcoming B-Series product with ImgAssist AI 2.0 has been revealed to elevate these capabilities further, backed by substantial investment from the Cancer Prevention and Research Institute of Texas, which awarded the company a grant worth up to $7.4 million.
Company Mission and Vision
At its core, Perimeter Medical Imaging AI strives to transform how cancer surgeries are performed. With both the S-Series and soon-to-launch B-Series systems, the company's focus remains on addressing unmet medical needs in the surgical landscape. The advances in imaging technology aim to facilitate surgeons in making better-informed decisions, leading to enhanced patient outcomes and a potential reduction in surgical complications.
Company Stock Information
Perimeter Medical Imaging AI Inc. will continue trading on the TSXV under the symbol “PINK,” while transitioning to the OTCQX under the symbol “PYNKF.” This dual listing enhances the company’s exposure, providing investors with more avenues to engage with Perimeter’s evolving business strategy.
Frequently Asked Questions
What is the significance of Perimeter’s move to the OTCQX?
This move enhances visibility and provides greater access to U.S. investors, which is crucial for expanding its shareholder base.
What technologies does Perimeter Medical Imaging AI offer?
Perimeter offers the S-Series OCT system for real-time imaging and is developing the B-Series with ImgAssist AI 2.0 for enhanced surgical assistance.
How does the B-Series technology improve surgical outcomes?
The B-Series uses advanced imaging techniques to help ensure clearer surgical margins, potentially lowering reoperation rates amidst breast-conserving surgeries.
What recent clinical results has Perimeter achieved?
The company reported positive topline results indicating significant reduction in residual cancer cases during surgeries, supporting its upcoming FDA submission.
What is Perimeter’s mission in the medical field?
The company aims to innovate cancer surgery with advanced imaging solutions, significantly impacting treatment efficacy and patient experiences.
